A share price of Arcutis Biotherapeutics Inc [ARQT] is currently trading at $11.06, up 9.40%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ARQT shares have gain 5.94% over the last week, with a monthly amount glided 65.32%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 11, March 2024, Arcutis Promotes Todd Tucker to Chief Human Resources Officer. In a post published today on Yahoo Finance, Industry veteran with over 25 years’ experience will continue to advance the company culture and grow the capabilities of Arcutis’ workforce.
From an analyst’s perspective:
Arcutis Biotherapeutics Inc [NASDAQ: ARQT] stock has seen the most recent analyst activity on January 03, 2024, when Mizuho upgraded its rating to a Buy and also boosted its price target to $8 from $4. Previously, Mizuho downgraded its rating to Neutral on October 26, 2023, and dropped its price target to $4. On October 13, 2023, downgrade downgraded it’s rating to Neutral and revised its price target to $6 on the stock. Needham started tracking the stock assigning a Buy rating and suggested a price target of $46 on September 07, 2022. Goldman initiated its recommendation with a Buy and recommended $45 as its price target on March 17, 2022. Mizuho started tracking with a Buy rating for this stock on June 30, 2021, and assigned it a price target of $58. In a note dated May 27, 2021, Morgan Stanley upgraded an Overweight rating on this stock but restated the target price of $52.
Arcutis Biotherapeutics Inc experienced fluctuations in its stock price throughout the past year between $1.76 and $15.40. Currently, Wall Street analysts expect the stock to reach $32 within the next 12 months. Arcutis Biotherapeutics Inc [NASDAQ: ARQT] shares were valued at $11.06 at the most recent close of the market. An investor can expect a potential return of 189.33% based on the average ARQT price forecast.
Analyzing the ARQT fundamentals
Trailing Twelve Months sales for Arcutis Biotherapeutics Inc [NASDAQ:ARQT] were 3.69M which represents 1765.66% growth. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -4.04%, Pretax Profit Margin comes in at -4.35%, and Net Profit Margin reading is -4.39%. To continue investigating profitability, this company’s Return on Assets is posted at -0.77, Equity is -2.94 and Total Capital is -0.82. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.28.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.30 points at the first support level, and at 9.53 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.46, and for the 2nd resistance point, it is at 11.85.
Arcutis Biotherapeutics Inc [ARQT] reported earnings per share of -$0.72 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.77/share, meaning a difference of $0.05 and a surprise factor of 6.50%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.73 per share as compared to estimates of -$0.86 per share, a difference of $0.13 representing a surprise of 15.10%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Arcutis Biotherapeutics Inc [NASDAQ:ARQT] is 7.08. In addition, the Quick Ratio stands at 6.80 and the Cash Ratio stands at 1.91. Considering the valuation of this stock, the price to sales ratio is 290.17, the price to book ratio is 12.07.
Transactions by insiders
Recent insider trading involved Heron Patrick J, Director, that happened on Mar 04 ’24 when 21052.0 shares were purchased., Watanabe Todd Franklin completed a deal on Mar 04 ’24 to sell 14903.0 shares. Meanwhile, Burnett Patrick sold 4782.0 shares on Mar 04 ’24.
